373 related articles for article (PubMed ID: 30350309)
1. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
5. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
[TBL] [Abstract][Full Text] [Related]
6.
Batista R; Lima L; Vinagre J; Pinto V; Lyra J; Máximo V; Santos L; Soares P
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023888
[TBL] [Abstract][Full Text] [Related]
7. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
Castelo-Branco P; Leão R; Lipman T; Campbell B; Lee D; Price A; Zhang C; Heidari A; Stephens D; Boerno S; Coelho H; Gomes A; Domingos C; Apolonio JD; Schäfer G; Bristow RG; Schweiger MR; Hamilton R; Zlotta A; Figueiredo A; Klocker H; Sültmann H; Tabori U
Oncotarget; 2016 Sep; 7(36):57726-57736. PubMed ID: 27437772
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations in primary and secondary WHO grade III meningioma.
Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
[TBL] [Abstract][Full Text] [Related]
10. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
Roggisch J; Ecke T; Koch S
Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
[TBL] [Abstract][Full Text] [Related]
12. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
14.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
15. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer.
Faleiro I; Apolónio JD; Price AJ; De Mello RA; Roberto VP; Tabori U; Castelo-Branco P
Future Oncol; 2017 Oct; 13(23):2045-2051. PubMed ID: 29019414
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
[TBL] [Abstract][Full Text] [Related]
19. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
Hosen I; Rachakonda PS; Heidenreich B; de Verdier PJ; Ryk C; Steineck G; Hemminki K; Kumar R
Int J Cancer; 2015 Oct; 137(7):1621-9. PubMed ID: 25809917
[TBL] [Abstract][Full Text] [Related]
20. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.
Lee DD; Komosa M; Sudhaman S; Leão R; Zhang CH; Apolonio JD; Hermanns T; Wild PJ; Klocker H; Nassiri F; Zadeh G; Diplas BH; Yan H; Gallinger S; Pugh TJ; Ramaswamy V; Taylor MD; Castelo-Branco P; Nunes NM; Tabori U
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
